# US 2025/0375465 A1 · Methods for affecting tissue-resident t cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0375465 A1
- Document ID: US20250375465A1
- Status: Published application
- Kind: A1
- Application number: 19/193,495
- Filed: 2025-04-29
- Published: 2025-12-11
- Earliest claimed: 2024-04-29
- Assignees: The Trustees of the University of Pennsylvania
- Applicants: The Trustees of the University of Pennsylvania
- Inventors: Christoph T. Ellebrecht
- Web page: https://patentgrep.com/patent/US20250375465A1

## CPC

- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 31/395: having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K 38/1709: {from mammals}
- A61K 38/465: {acting on ester bonds (3.1), e.g. lipases, ribonucleases}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61P 17/00: Drugs for dermatological disorders
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C12N 5/0636: {T lymphocytes}
- C12N 5/10: Cells modified by introduction of foreign genetic material
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1138: {against receptors or cell surface proteins}
- C12Q 1/68: involving nucleic acids
- A61K 2039/505: {comprising antibodies}
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2510/00: Genetically modified cells
- C12Q 2600/136: Screening for pharmacological compounds
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Described herein are methods for reducing tissue resident memory T cells (TRM) in the skin, as well as a method for treating, ameliorating, and/or preventing autoimmune and inflammatory diseases or disorders in the skin. These methods include downregulating the expression of GSPT1 in the tissue resident T cells. Also described are methods for screening therapeutic targets for regulating T cell functions.

## Claims

### Claim 1

A method of reducing skin-homing T cells or tissue-resident memory T cells (TRM) in a skin tissue, comprising contacting the skin-homing T cells or TRM with an effective amount of a composition that downregulates an expression level and/or an activity of GSPT1.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition comprises at least one selected from the group consisting of:
a small molecule inhibitor of GSPT1,
a protein inhibitor of GSPT1,
a nucleic acid that downregulates the expression level and/or activity of GSPT1 by RNA interference, and/or an expression vector expressing the nucleic acid that downregulates the expression level and/or activity of GSPT1 by RNA interference,
a ribozyme that downregulates the expression level and/or activity of GSPT1, and/or an expression vector expressing the ribozyme,
an expression vector comprising an expression cassette, wherein the expression cassette expresses CRISPR components that downregulate the expression level and/or activity of GSPT1 by CRISPR knockout or CRISPR knockdown, and
a trans-dominant negative mutant protein of GSPT1, and/or an expression vector that expresses the trans-dominant negative mutant protein of GSPT1.

### Claim 3 (depends on 1)

The method of claim 1, wherein the composition is delivered by a T cell-specific delivery method.

### Claim 4 (depends on 1)

The method of claim 1, wherein the composition comprises a lipid nanoparticle (LNP) that is conjugated to an antibody targeting a T cell specific surface antigen.

### Claim 5 (depends on 4)

The method of claim 4, wherein the T cell specific surface antigen is CD5.

### Claim 6 (depends on 1)

The method of claim 1, wherein the CRISPR components comprise one or more guide RNAs comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 6, and a combination of SEQ ID NO: 5 and SEQ ID NO: 6.

### Claim 7 (depends on 1)

The method of claim 1, wherein the composition comprises a molecular degrader that links GSPT1 to a ubiquitin ligase.

### Claim 8 (depends on 1)

The method of claim 1, wherein the composition comprises a small molecule inhibitor of GSPT1, and wherein the small molecule inhibitor of GSPT1 comprises at least one selected form the group consisting of SP-3204, CDG0501,

### Claim 9 (depends on 1)

The method of claim 1, wherein administering an effective amount of the composition causes apoptosis in the TRM cells in the skin tissue.

### Claim 10 (depends on 1)

The method of claim 1, wherein at least one of the following applies:
(i) the skin tissue is an isolated skin tissue; or
(ii) the skin tissue is in a subject.

### Claim 11 (depends on 1)

The method of claim 1, wherein the skin tissue is in a subject, and wherein the subject is a mammal, optionally a human.

### Claim 12

A method of selectively depleting T cells in the skin, comprising:
contacting T cells in the skin with a composition that downregulates an expression level and/or an activity of GSPT1.

### Claim 13 (depends on 12)

The method of claim 12, wherein the composition comprises at least one selected from the group consisting of:
a small molecule inhibitor of GSPT1,
a protein inhibitor of GSPT1,
a nucleic acid that downregulates the expression level and/or activity of GSPT1 by RNA interference, and/or an expression vector expressing the nucleic acid that downregulates the expression level and/or activity of GSPT1 by RNA interference,
a ribozyme that downregulates the expression level and/or activity of GSPT1, and/or an expression vector expressing the ribozyme,
an expression vector comprising an expression cassette, wherein the expression cassette expresses CRISPR components that downregulate the expression level and/or activity of GSPT1 by CRISPR knockout or CRISPR knockdown, and
a trans-dominant negative mutant protein of GSPT1, and/or an expression vector that expresses the trans-dominant negative mutant protein of GSPT1.

### Claim 14 (depends on 12)

The method of claim 12, wherein the composition is delivered by a T cell-specific delivery method.

### Claim 15 (depends on 12)

The method of claim 12, wherein the composition comprises a lipid nanoparticle, wherein the lipid nanoparticle is conjugated to an antibody targeting a T cell specific surface antigen.

### Claim 16 (depends on 15)

The method of claim 15, wherein the T cell specific surface antigen is CD5.

### Claim 17 (depends on 12)

The method of claim 12, wherein the CRISPR components comprise one or more guide RNAs comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 6, and a combination of SEQ ID NO: 5 and SEQ ID NO: 6.

### Claim 18 (depends on 12)

The method of claim 12, wherein the composition comprises a molecular degrader that links GSPT1 to a ubiquitin ligase.

### Claim 19 (depends on 12)

The method of claim 12, wherein the composition comprises a small molecule inhibitor of GSPT1, and wherein the small molecule inhibitor of GSPT1 comprises at least one compound selected form the group consisting of SP-3204, CDG0501,

### Claim 20 (depends on 12)

The method of claim 12, wherein administering an effective amount of the compound causes apoptosis in the TRM cells in the skin tissue.

### Claim 21 (depends on 12)

The method of any one of claim 12, wherein at least one of the following applies:
(i) the skin tissue is an isolated skin tissue; or
(ii) the skin tissue is in a subject.

### Claim 22 (depends on 12)

The method of claim 12, wherein the skin tissue is in a subject, and wherein the subject is a mammal, optionally a human.

### Claim 23

A method of treating, ameliorating and/or preventing an autoimmune or inflammatory disease or disorder in a skin in a subject in need thereof, comprising:
administering to the subject an effective amount of a composition that downregulates an expression level and/or an activity of GSPT1.

### Claim 24 (depends on 23)

The method of claim 23, wherein the autoimmune or inflammatory disease or disorder in the skin is alopecia areata, graft-versus-host disease (GVHD), lichen planus, lupus erythematosus, scleroderma (optionally localized forms such as morphea), psoriasis and related conditions such as psoriatic arthritis, Stevens-Johnson syndrome, urticarial vasculitis, vitiligo, atopic dermatitis (eczema), or bullous pemphigoid.

### Claim 25 (depends on 23)

The method of claim 23, wherein the composition comprises at least one selected from the group consisting of:
a small molecule inhibitor of GSPT1,
a protein inhibitor of GSPT1,
a nucleic acid that downregulates the expression level and/or activity of GSPT1 by RNA interference, and/or an expression vector expressing the nucleic acid that downregulates the expression level and/or activity of GSPT1 by RNA interference,
a ribozyme that downregulates the expression level and/or activity of GSPT1, and/or an expression vector expressing the ribozyme,
an expression vector comprising an expression cassette, wherein the expression cassette expresses CRISPR components that downregulate the expression level and/or activity of GSPT1 by CRISPR knockout or CRISPR knockdown, and
a trans-dominant negative mutant protein of GSPT1, and/or an expression vector that expresses the trans-dominant negative mutant protein of GSPT1.

### Claim 26 (depends on 23)

The method of claim 23, wherein the composition is delivered by a T cell-specific delivery method.

### Claim 27 (depends on 23)

The method of claim 23, wherein the compound further comprises a lipid nanoparticle, wherein the lipid nanoparticle is conjugated to an antibody targeting a T cell specific surface antigen.

### Claim 28 (depends on 27)

The method of claim 27, wherein the T cell specific surface antigen is CD5.

### Claim 29 (depends on 25)

The method of claim 25, wherein the CRISPR components comprise one or more guide RNAs comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 6, and a combination of SEQ ID NO: 5 and SEQ ID NO: 6.

### Claim 30 (depends on 23)

The method of claim 23, wherein the composition comprises a molecular degrader that links GSPT1 to a ubiquitin ligase.

### Claim 31 (depends on 23)

The method of claim 23, wherein the composition comprises a small molecule inhibitor of GSPT1, and wherein the small molecule inhibitor of GSPT1 comprises at least one selected form the group consisting of SP-3204, CDG0501,

### Claim 32 (depends on 23)

The method of claim 23, wherein administering the composition causes apoptosis in skin-homing T cells.

### Claim 33 (depends on 23)

The method of claim 23, wherein administering the composition causes apoptosis in the skin tissue resident memory T cells (TRMs).

### Claim 34 (depends on 23)

The method of claim 23, wherein the composition is a pharmaceutical composition.

### Claim 35 (depends on 23)

The method of claim 23, wherein the composition is administered topically, orally, or parentally.

### Claim 36 (depends on 23)

The method of claim 23, wherein the subject is a mammal, optionally a human.

### Claim 37

A pharmaceutical composition, comprising:
a compound that downregulates an expression level and/or an activity of GSPT1; and
a pharmaceutically acceptable carrier,
wherein the pharmaceutical composition is formulated as a topical formulation.

### Claim 38

A method for treating, ameliorating, and/or preventing an autoimmune or inflammatory disease or disorder in a skin in a subject in need thereof, the method comprising administering an effective amount of the pharmaceutical composition comprising:
a compound that downregulates an expression level and/or an activity of GSPT1; and
a pharmaceutically acceptable carrier,
wherein the pharmaceutical composition is formulated as a topical formulation.

### Claim 39 (depends on 38)

The method of claim 38, wherein the autoimmune or inflammatory disease or disorder is selected from the group consisting of alopecia areata, graft-versus-host disease (GVHD), lichen planus, lupus erythematosus, scleroderma, localized scleroderma such as morphea, psoriasis, psoriasis-related conditions such as psoriatic arthritis, Stevens-Johnson syndrome, urticarial vasculitis, vitiligo, atopic dermatitis (eczema), and bullous pemphigoid.

### Claim 40 (depends on 38)

The method of claim 38, wherein the compound comprises at least one selected from the group consisting of:
a small molecule inhibitor of GSPT1,
a protein inhibitor of GSPT1,
a nucleic acid that downregulates the expression level and/or activity of GSPT1 by RNA interference, and/or an expression vector expressing the nucleic acid that downregulates the expression level and/or activity of GSPT1 by RNA interference,
a ribozyme that downregulates the expression level and/or activity of GSPT1, and/or an expression vector expressing the ribozyme,
an expression vector comprising an expression cassette, wherein the expression cassette expresses CRISPR components that downregulate the expression level and/or activity of GSPT1 by CRISPR knockout or CRISPR knockdown, and
a trans-dominant negative mutant protein of GSPT1, and/or an expression vector that expresses the trans-dominant negative mutant protein of GSPT1.

### Claim 41 (depends on 38)

The method of claim 38, wherein the composition is formulated for a T cell-specific delivery method.

### Claim 42 (depends on 38)

The method of claim 38, wherein composition comprises a lipid nanoparticle (LNP) conjugated to an antibody targeting a T cell specific surface antigen.

### Claim 43 (depends on 42)

The method of claim 42, wherein the T cell specific surface antigen is CD5.

### Claim 44 (depends on 40)

The method of claim 40, wherein the CRISPR components comprise one or more guide RNAs comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 5, SEQ ID NO: 6, and a combination of SEQ ID NO: 5 and SEQ ID NO: 6.

### Claim 45 (depends on 40)

The method of claim 40, wherein the compound comprises a molecular degrader that links GSPT1 to a ubiquitin ligase.

### Claim 46 (depends on 40)

The method of claim 40, wherein the compound comprises a small molecule inhibitor of GSPT1, and wherein the small molecule inhibitor of GSPT1 comprises at least one selected form the group consisting of SP-3204, CDG0501,

### Claim 47 (depends on 38)

The method of claim 38, wherein the composition is formulated as a cream, a gel, a lotion, an ointment, a patch, a paste, a self-sticking membrane, or a spray.

### Claim 48

A method of screening for therapeutic targets for regulating T cell function in a tissue of interest, comprising:
preparing a pool of genetically engineered T cells, wherein all or some of the genetically engineered T cells comprises one or more knocked-out or disrupted genes;
introducing the pool of genetically engineered T cells into a subject carrying the tissue of interest;
collecting T cells from a plurality of tissues including the tissue of interest;
detecting genes that are knocked-out or disrupted in the T cells,
wherein
a gene is determined to inhibit T cell function in the tissue of interest if the gene is knocked-out or disrupted at a higher rate in T cells in the tissue of interest than in other tissues, or
a gene is determined to enhance T cell function in the tissue of interest if the gene is knocked-out or disrupted at a lower rate in T cells in the tissue of interest than in other tissues.

### Claim 49 (depends on 48)

The method of claim 48, wherein the genetically engineered T cells and the tissue of interest is originated from a first species, and wherein the subject is from a second species different from the first species.

### Claim 50 (depends on 49)

The method of claim 49, wherein the first species is human, and the second species is a non-human species, optionally an immunodeficient non-human species.

### Claim 51 (depends on 48)

The method of claim 48, wherein the method screens genes that cause or are associated with a T cell-mediated autoimmune disease in the tissue of interest, and wherein a gene is determined to cause or associate with the T cell-mediated autoimmune disease in the tissue of interest if the gene is knocked-out or disrupted at a higher rate in T cells found in the tissue of interest than in other tissues.

### Claim 52 (depends on 48)

The method of claim 48, wherein the method screens genes that promote T cell mediated anti-cancer immunity, and wherein a gene is determined to promote T cell mediated anti-cancer immunity against a cancer tissue if the gene is knocked-out or disrupted at a lower rate in T cells found in the cancer tissue than in other tissues.

### Claim 53 (depends on 48)

The method of claim 48, wherein preparing the pool of genetically engineered T cells comprises editing T cells with a CRISPR gene editing system comprising a gRNA library comprising gRNAs for targeting a plurality of genes in the T cells.

### Claim 54 (depends on 53)

The method of claim 53, wherein the gRNA library is a genome-wide gRNA library.

### Claim 55 (depends on 48)

The method of claim 48, further comprising confirming that the gene identified in the screening inhibits or enhances T cell function.

### Claim 56 (depends on 55)

The method of claim 55, wherein confirming that the gene identified in the screening inhibits or enhances T cell function comprises:
introducing T cells into a subject carrying the tissue of interest;
isolating a plurality of tissues including the tissue of interest;
detecting a level of the gene identified in the screening,
wherein the gene is confirmed to inhibit T cell function in the tissue of interest if the level of the gene is reduced in the tissue of interest as compared to that in other tissues, and
wherein the gene is confirmed to enhance T cell function in the tissue of interest if the level of the gene is increased in the tissue of interest as compared to that in other tissues.
